Stem cell transplantation was introduced as a new therapeutic modality for amyloidosis. The purpose of the current study was to determine the feasibility and toxicity of stem cell transplantation for amyloidosis in a cooperative group setting in which most participating institutions would have limited experience in managing the disorder. A total of 30 patients with biopsy-proven amyloidosis shown to be immunoglobulin light-chain type were enrolled on this trial. The protocol required mobilization of a minimum of 6 Â 10 8 mononuclear cells/ kg or 5 Â 10 6 CD34 þ cells/kg ideal body weight. These targets had to be achieved within seven collections. Patients with advanced hepatic, renal, or cardiac failure were excluded. End points included objective response rate and overall survival. The secondary end point of the protocol was nonhematologic toxicity. Accrual to the study was faster than expected. The overall response rate (hematologic and organ) was 64%, with three treatmentrelated deaths. Another patient died before day 30 of sudden cardiac death not treatment related. The median follow-up of surviving patients is 30.3 months. Median survival has not been reached. Stem cell transplantation for selected patients with amyloidosis is feasible in a cooperative group setting. A multicenter phase 3 trial of high-dose therapy is indicated.
The first report 1 of dose-intensive therapy with autologous stem cell support for the treatment of primary amyloidosis (AL) was published 8 years ago. Most published reports originate from two centers in the United States, owing to the rare nature of the disorder. 2 There have been a dozen reported series that have features in common. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] The treatment-related mortality is nearly five-fold that of autologous stem cell transplantation for other hematologic malignancies, an outcome related to end-organ damage due to the amyloid. 15 The reported response rates of 60%, both end-organ and hematologic, are significantly higher than those achievable with oral melphalan and prednisone. 16, 17 Patients who have received stem cell transplants for amyloid are highly selected. Therefore, there is considerable uncertainty as to what the actual value of the technique is in terms of its ability to improve survival in the entire clinical spectrum of patients with AL. 18 Ultimately, this question will be answered only by a phase 3 cooperative group study. It was not known, however, whether centers that perform transplantations on one or two patients with AL per year could achieve results comparable to those reported from centers that see large numbers of AL patients. Therefore, this pilot study was developed to determine response and survival of AL patients. In addition, we hoped to gain knowledge about feasibility and toxicity for a future large-scale phase 3 trial to assess the value of stem cell transplantation in this rare disorder. Other questions included, would accrual goals be met, would participation at multiple centers occur, and would the treatment-related mortality be different than that reported from larger centers with large AL patient cohorts. Because the Eastern Cooperative Oncology Group (ECOG) has extensive experience treating patients with multiple myeloma [19] [20] [21] [22] [23] and has a certification process for approval to perform transplantation on ECOG studies, a phase 2 study in patients with AL was initiated.
Patients and methods
The primary end points of the study were the response rate and the overall survival of patients with biopsy-proven AL after high-dose melphalan with hematopoietic stem cell reconstitution. A secondary end point was to evaluate the toxicity of high-dose melphalan for the treatment of AL.
Strict eligibility criteria were in place to ensure patients with multiorgan AL could withstand the complications associated with myeloablative chemotherapy. The criteria included a histologic diagnosis of AL with positive Congo red stain and green birefringence under polarized light and the presence of a monoclonal protein determined by immunoelectrophoresis or immunofixation in the serum or urine (or both) to ensure that the AL was of immunoglobulin light-chain origin. Patients with overt multiple myeloma were excluded. For the purpose of this study, multiple myeloma was defined as the presence of lytic bone disease or pathologic fractures. Patients whose bone marrow contained X30% plasma cells were ineligible. Patients whose only manifestation of AL was carpal tunnel syndrome or purpura and who had no visceral syndrome were not eligible. Patients who might have secondary, familial, or localized amyloidosis were ineligible. The ECOG performance status had to range from 0 to 2. The following minimal laboratory features were required: granulocytes X1000/ml, platelets X100 000/ml, direct bilirubin p2 mg/dl, alkaline phosphatase o4 times the institutional upper limit of normal, and serum creatinine p2 mg/dl. The echocardiogram had to show an ejection fraction X50% with an interventricular septal wall thickness p15 mm. Patients with cardiac amyloid had to have a New York Heart Association classification of I. On pulmonary function tests, the diffusing capacity for carbon monoxide had to be X50%, the forced vital capacity X60%, and the forced expiratory volume in 1 s X55% of predicted.
Prior therapy was allowed before study registration; however, patients could not have had more than two cycles of prior chemotherapy (one regimen only). The lifetime cumulative dose of melphalan could not exceed 150 mg, and no melphalan therapy was permitted within 4 weeks before registration. Patients with active infection were not eligible. Protocol activation required Institutional Review Board approval of each participating institution. All patients gave written informed consent before enrollment.
Treatment
All patients had a central venous catheter placed for collection of stem cells and subsequent transplantation. The mobilization schedule was filgrastim 10 mg/kg (actual body weight) administered subcutaneously daily, with apheresis beginning on day 5 and continued until collections were completed. The goal was to obtain either 6 Â 10 8 mononuclear cells/kg or 5 Â 10 6 CD34 þ cells/kg ideal body weight. If these targets were not achieved after a maximum of seven collections, the patient was considered to have inadequate stem cell product and was removed from the study because of engraftment concerns.
Within 30 days after the last day of collection, patients were conditioned with melphalan 200 mg/m 2 (ideal body weight) given intravenously on day À1, followed by stem cell infusion the next day (day 0). No patients received a reduction in melphalan dose. A minimum of 18 h had to elapse between the melphalan administration and the stem cell infusion. Beginning on day þ 1, filgrastim 5 mg/kg (actual body weight) was administered subcutaneously daily until the neutrophil count was greater than 1000/ml for 3 consecutive days. The dose of filgrastim was rounded to 300 mg for patients who weighed less than 60 kg and to 480 mg for those more than 60 kg to match commercially available vial sizes of filgrastim.
Assessment of response
Response criteria were published previously. 24 Briefly, a response in AL can be either organ based, with evidence of improvement of an organ known to be involved with amyloid, or hematologic based, following criteria of response established for stem cell transplantation in multiple myeloma. 25 For patients with steatorrhea or small bowel involvement, there needed to be a 50% reduction in fecal fat excretion and normalization of the serum carotene value. For patients with peripheral neuropathy, improvement had to be documented on electromyogram and nerve conduction velocity test. In patients with nephrotic-range proteinuria (43 g/24 h), a 50% reduction in 24-h urine albumin was required in the absence of progression of the creatinine value. If hepatomegaly was present 43 cm below the right costal margin, response required complete normalization of hepatomegaly measured in the midclavicular line and normalization or a 50% reduction in the alkaline phosphatase value. For patients with echocardiographic evidence of amyloid, a cardiac response required a X2-mm decrease in interventricular septal wall thickness. The minor response criteria included a 25-50% reduction in serum alkaline phosphatase value in patients with hepatic amyloid and a two-grade improvement in ECOG performance status. A hematologic response required disappearance of the serum and urine monoclonal protein on immunofixation. Of note, clinical responses in AL post transplantation may continue for up to and occasionally exceed 1 year. Patients who failed to meet these response criteria were considered stable. Progression was defined as a 30% increase in palpable hepatomegaly or a 50% increase in alkaline phosphatase level, a doubling of the urinary albumin loss or an increase of X2 g/24 h, an increase in serum creatinine to X3 mg/dl, or echocardiographic evidence of wall thickening by X3 mm. A decrease in serum albumin of 1 g/dl, a decline in ECOG performance status by two grades, or a doubling of serum bilirubin value was also considered progression. Survival was not considered a response criterion owing to the selection inherent in accruing these patients, but it was monitored.
Statistical methods
Because organ responses in AL are known to occur slowly even when there is complete suppression of the amyloid light-chain production, this study was designed with a onestage accrual goal. With 28 eligible patients, this study had 90% power, at the two-sided 0.05 significance level, to detect a target response rate of 60% compared with a null response rate of 31%. The target response rate for this study abstracted from published literature was 60%. Toxicity was analyzed with National Cancer Institute Common Toxicity Criteria v 2.0. Survival was analyzed by the method of Kaplan and Meier. 26 
Results
The study was activated on July 31, 1998. Only one amendment was enacted while the study was ongoing regarding stopping rules and dosing modifications for filgrastim. The study closed on May 15, 2000. The 30 patients were entered by 12 different ECOG transplant centers. Of the 30 patients accrued, two were ruled ineligible. One patient, at the time of study entry, had an interventricular septal thickness 415 mm. A second patient had both serum and urine immunofixation negative for light chain and lytic bone disease was present, reflecting overt multiple myeloma. A total of 28 eligible patients were included in the analysis for response, whereas all 30 patients were considered for toxicity analysis. Table 1 summarizes the on-study characteristics of the 28 eligible patients. The median age was 54 years (range, 42-71 years). Table 2 provides data for some of the continuous variables for the 28 patients.
Patient cohort

Toxicity
Treatment-related toxicity information is summarized in Table 3 . Hematologic toxicities were excluded in the calculation of the worst degree of toxicity because of the anticipated high prevalence of grade 4 hematologic toxicities with myeloablative chemotherapy.
Response
Of the 28 eligible patients, a major response was seen in 14. There were an additional four minor responses. There were five patients whose best response was stable disease. There was one patient with progressive disease and four nonevaluable patients. The overall response rate combining major and minor responses was 64% (18 of 28). The 95% confidence interval was 44.1-81.4%. Among patients who achieved a major response, 12 of the 14 are alive without disease progression, one is alive but the disease has progressed, and one had disease progression and died. Among the four patients who achieved a minor response, all are alive without disease progression. Among the five patients whose best response was stable disease, one is alive without disease progression, two are alive with disease progression, and two died after disease progression.
The four patients who were considered nonevaluable for response included one patient with each of the following: cardiac arrest on day þ 7, multiorgan failure on day þ 15, disease progression and death 2.4 months after transplantation, and death during stem cell infusion. Three of these deaths are considered treatment related, for an overall treatment-related mortality of 10%. A fourth patient died suddenly at home 2.4 months after transplantation, presumably of an arrhythmia, and the relationship to treatment could not be confirmed but raises the mortality rate within the first 100 days after transplantation to 14%.
The median duration of remission has not been reached because only two responding patients have had disease progression. Response duration, however, has ranged from 0 to 32 months. The median overall survival among the 28 eligible patients has not been reached, but at 2 years, 86% were alive, and at 3 years, 62% were alive. The median follow-up among surviving patients is 30.3 months.
There were 11 patients whose worst nonhematologic toxicity grade was X4. There were three patients with grade 5 toxicities. One patient died on day þ 7, after peripheral blood stem cell infusion, of cardiopulmonary arrest. On day þ 3, this patient had alveolar damage with bilateral lung infiltrates. A second patient developed multiorgan failure and died 15 days after receiving melphalan. A third patient died with cardiac ischemia on day þ 1 after peripheral blood stem cell infusion.
Discussion
AL results from the expansion of a clonal population of plasma cells that produces an insoluble immunoglobulin light-chain fragment that deposits in tissues leading to organ dysfunction and, ultimately, to the death of the patient. 27 Two prospective randomized clinical trials have shown that treatment with oral melphalan and prednisone results in objective responses and improved survival 16, 17 in a minority of patients. However, because the median overall survival remains only 18 months with standard therapy, new strategies are required. Other myeloma-based therapies have been used for the treatment of AL, including high-dose dexamethasone, [28] [29] [30] [31] interferon, and VBMCP (vincristine, carmustine, melphalan, cyclophosphamide, and prednisone). 32 Because higher-dose therapy with stem cell transplantation has been shown to improve survival in patients with multiple myeloma, 33 it was logical to apply this modality to patients with AL. The low plasma cell burden in patients with amyloid compared to myeloma favors significant responses to dose-intensive therapy. Elimination of the plasma cells responsible for producing the amyloid light chain stops deposition and presumably slowly improves organ function, because the amyloid deposits are in dynamic equilibrium and are not static. 34 Several reports in the literature have indicated that there is a substantially higher response rate in patients after transplantation 2,5,11,14 compared to conventional therapy. Dispenzieri et al, 18 however, have demonstrated that this population is highly selected, and ability to undergo stem cell transplantation is a favorable prognostic feature for survival. The reported results on these highly selected patients might not necessarily hold true if a sicker population was eligible for enrollment. At Mayo Clinic, only 40% of all AL patients evaluated ultimately undergo high-dose therapy. This reflects the degree of selection that occurs. Because there are no phase 3 studies comparing standard therapy to high-dose therapy, the management of AL with stem cell transplantation is extrapolated from the existing literature. The decision is critical, unlike multiple myeloma, in which the anticipated mortality from transplantation is 1-2% in newly diagnosed patients. The published mortality associated with AL ranges from 15 to 40%. 35 In patients who receive transplants for multiple myeloma, visceral organ function is virtually always normal, and the primary problem is the marrow disorder. In AL, most patients are hematologically normal yet have significant organ dysfunction at the site of amyloid deposition: heart, liver, nerve, kidney, or lung. Patients may die of cardiac arrhythmias, 8 fatal pulmonary toxicity, 36 intractable cardiac failure, 7 gastrointestinal tract bleeding, 37 or precipitous renal failure, 15 which is rarely if ever seen in multiple myeloma. The decision to treat a patient with AL by transplantation must be undertaken with extreme caution, and ultimately a phase 3 trial to assess transplantation will be necessary, so the mistakes of transplantation for breast cancer are not repeated. A phase 3 trial in a disorder whose incidence is eight per million per year 38 and in which we estimate only one-third of patients diagnosed will be eligible for high-dose therapy could be initiated only as a national multicenter cooperative study. Before committing the resources for such a study, several questions need to be answered. First, are small centers willing to activate protocols for which the accrual is expected to be small? Nine of the centers that accrued in this study contributed only one patient each, but this amounted to one-third of the accrual goal for this protocol. Second, can the accrual goal be met in a reasonable time? This study was completed in 21 months; however, local Institutional Review Board activation of each protocol varied from center to center. Third, can centers with limited experience in transplantation for patients with amyloid achieve results comparable to those reported from large centers? Three of the 30 patients in this study were considered treatment-related deaths, which is similar to rates published from centers in the United States that perform transplantation on large numbers of AL patients. Fourth, will there be differences in responses in the multicenter setting compared with a single center? The response rate for this study was virtually identical to that published from larger centers. Large-center vs small-center analysis revealed no difference in mortality or response, but the numbers were small, and the study was not designed to detect such differences.
We conclude that a carefully conceived protocol open at multiple sites can produce results both in terms of response and toxicity equivalent to more experienced centers. The treatment-related mortality of 10% and the response rate of 64% are comparable to rates at large centers and suggest that a national multicenter phase 3 study of stem cell transplantation for AL randomizing patients to high-dose therapy vs standard-dose therapy is feasible.
